Drug Discovery World

OCTOBER 5, 2023

Experts and thought leaders in cancer research, precision medicine and immunotherapy will describe the latest research and the role of technology to help discover targets, develop cancer therapeutics and vaccines and, get to market faster. More to be announced.

Research 52

Research Antibody Medicine RNA 52

Drug Discovery World

OCTOBER 11, 2023

Experts and thought leaders in cancer research, precision medicine and immunotherapy will describe the latest research and the role of technology to help discover targets, develop cancer therapeutics and vaccines, and get to market faster. So who are they?

Research 52

Research Antibody RNA Engineer 52

Drug Discovery World

NOVEMBER 15, 2022

Applications: The ability to synthesise longer, accurate DNA sequences opens up a vast array of application possibilities: generating CRISPR libraries, in situ hybridisation probes, antibody libraries, vaccines, and so on, along with the ability to engineer metabolic pathways, microbes, and plants. .

DNA 98

DNA Drugs Antibody Engineer 98

Pharmaceutical Technology

FEBRUARY 1, 2023

Since the FDA approved AstraZeneca’s monoclonal antibody therapy Synagis (palivizumab) 25 years ago, drug development successes for RSV have been few and far between. In 2013, this changed when an NIH lab reported the structure of the RSV protein, leading to the exploration of the RSV structure in ways that were not previously possible.

Vaccination 162

Vaccination Vaccine Antibody FDA Approval 162

Pharmaceutical Technology

APRIL 27, 2023

Genomic medicine development was ranked as the top industry trend for 2023 in a survey of 198 GlobalData Pharma clients and prospects conducted between October and November 2022. GlobalData pharmaceutical analysts project that RNA-based gene therapies for oncology will grow from zero in 2022 to $4.6 billion by 2028. billion by 2028.

Manufacturing 130

Manufacturing RNA Contamination Vaccination 130

Drug Discovery World

AUGUST 4, 2023

RNA-based immunotherapy eradicates melanoma tumours Investigators at the Icahn School of Medicine at Mount Sinai have designed an RNA-based strategy to activate dendritic cells that eradicated tumours and prevented their recurrence in mouse models of melanoma.

Drugs 52

Drugs RNA Gene Scientist 52

XTalks

JUNE 5, 2023

Abrysvo is an unadjuvanted vaccine and is composed of two preF proteins selected to optimize protection against RSV A and B strains. “A In February 2023, Pfizer revealed that the European Medicines Agency (EMA) has accepted the Marketing Authorization Application (MAA) for Abrysvo. What is the Price of Abrysvo?

Vaccination 98

Vaccination Vaccine FDA Approval Protein 98

Delveinsight

AUGUST 26, 2021

Shape’s RNA editing technologies can modify the RNA sequence, which makes the body’s protein building blocks. This system is designed to deliver RNA editing technology or other payloads directly to particular body areas, such as the nervous system or muscle. was swooped up by Real Chemistry in January.

Vaccination 98

Vaccination Vaccine Gene Therapy RNA 98

Worldwide Clinical Trials

MAY 30, 2024

was withdrawn, rendering it unapproved for patient use, based on negative review comments by the Committee for Medicinal Products for Human Use. Tofersen (Intrathecal injection) This is an antisense oligonucleotide (ASO) that targets SOD1 mRNA to reduce the synthesis of SOD1 protein. The MAA file in the E.U.

Gene 162

Gene Clinical Trials Clinical Trials Gene Therapy 162

Pharmaceutical Technology

DECEMBER 9, 2022

Beyond our expertise in small molecules, we have built a solid reputation with biopharmaceutical companies for the characterisation and analysis of monoclonal antibodies, therapeutic proteins and biosimilars. All our equipment is in line with the latest European Medicines Agency (EMA) and FDA methods. HQ ADDRESS: Römerpark 2.

Development 130

Development Production Manufacturing Vaccination 130

pharmaphorum

DECEMBER 1, 2020

Pfizer and BioNTech have filed their COVID-19 vaccine with the European medicines regulator, paving the way for a potential approval before the end of the year. The EMA has also confirmed it has received a filing from Moderna, which is producing a rival vaccine based on similar RNA technology.

Vaccination 66

Vaccination Vaccine RNA Clinical Trials 66

pharmaphorum

NOVEMBER 23, 2020

The AZ vaccine also has a considerable convenience advantage over RNA-based vaccines from Pfizer and Moderna. The body produces antibodies against the protein, which neutralise the coronavirus in the event of an infection. AZ announced the news as reports suggested the UK could approve Pfizer’s rival by the end of the week.

Vaccination 103

Vaccination Vaccine Regulation Protein 103

pharmaphorum

AUGUST 18, 2020

The Corona Accelerated R&D in Europe (CARE) has been hastily set up by Europe’s Innovative Medicines Initiative (IMI), focusing on tackling the pandemic that has wreaked so much havoc across the world this year. The consortium aims to rapidly develop drugs to fight SARS-CoV-2 and find virus neutralising antibodies.

Protein 97

Protein Pharma Companies RNA Drugs 97

pharmaphorum

DECEMBER 13, 2021

Dormitzer comes from Pfizer, where he was chief scientific officer for RNA and viral vaccines for more than six years. AZ said the deal would go beyond Covid-19 and extend into other RNA-based therapeutics. Like Sanofi, Biogen has invested in AI for RNA-based therapeutics this year, announcing a collaboration with Envisagenics.

RNA 94

RNA Vaccination Vaccine Development 94

Drug Discovery World

JULY 18, 2023

Rolf Turk , Senior Manager, Genomics Medicine at Integrated DNA Technologies, examines how CRISPR is being used to enhance cancer therapies. These efforts, along with many others, are opening doors for new possibilities in translational medicine. parvovirus B19, Flaviviridae, Ebola, and Coronaviridae), DNA viruses (e.g.,

DNA 98

DNA Genome Genomics RNA 98

The Pharma Data

AUGUST 16, 2021

Better activation of innate and adaptive immune responses was achieved with CV2CoV, resulting in faster response onset, higher titers of antibodies, and stronger memory B and T cell activation as compared to the first-generation candidate, CVnCoV. The full manuscript of the preclinical data is available on the pre-print server bioRxiv. “In

Immune Response 52

Immune Response Vaccination Vaccine Antibody 52

pharmaphorum

OCTOBER 16, 2020

Sanofi will shortly start human trials of a second coronavirus vaccine, developed with US biotech Translate Bio, after reporting that it stimulated antibodies against SARS-CoV-2 in preclinical testing. It started human testing of a protein subunit vaccine with partner GlaxoSmithKline last month. Chinese inactivated vaccine safe.

Trials 91

Trials Vaccination Vaccine Antibody 91

The Pharma Data

JANUARY 21, 2021

Luckily, the new variants still rely on the coronavirus’ “spike protein” to infect cells, and the two COVID vaccines now on the U.S. market specifically target the spike protein to prevent transmission, explained Dr. Kathryn Edwards, scientific director of the Vanderbilt University Vaccine Research Program in Nashville.

Vaccination 52

Vaccination Vaccine Protein Immune Response 52

The Pharma Data

DECEMBER 8, 2020

Since partnering with Eli Lilly to produce the first monoclonal antibody therapy approved for mild-to-moderate COVID-19 patients, antibody discovery company AbCellera is going big on the Nasdaq. Laying down a new track for RNA processing, Remix launched with $81 million in financing. Reduce cost. Nuance Pharma .

RNA 52

RNA Antibody Life Science Protein 52

pharmaphorum

OCTOBER 6, 2020

The European Medicines Agency has begun a second “rolling review” of a potential coronavirus vaccine jointly developed by BioNTech and Pfizer, setting up a race with a rival from AstraZeneca and Oxford University.

Vaccination 57

Vaccination Vaccine RNA Immune Response 57

Drug Discovery World

APRIL 6, 2023

from Fabien Vincent, Pfizer, Groton, US High content phenotypic and pathway profiling identifies novel drug mechanisms-of-action tailored towards cancers of unmet need by Neil Carragher, University of Edinburgh, Edinburgh, UK Functional genomics as an enabling tool for phenotypic screening by Matthew Garnett Chemistry to the Clinic: Part 1-3: (..)

Protein 52

Protein Clinical Trials Clinical Trials Antibody 52

The Pharma Data

MARCH 8, 2022

The virus carries the information to produce a series of proteins, capable of inhibiting antiviral recognition systems of the infected cell. Actually, these systems could identify viral genetic material (here: Ribonucleic acids/RNAs) and sound the alarm. For example, viral RNAs are masked by the addition of a methyl group.

Immune Response 52

Immune Response RNA Protein Genetics 52

Drug Discovery World

JUNE 6, 2023

He is also a professor of medicine and immunology at the University of Washington School of Medicine. Jordan also commented on a resurgence in antibody drug conjugates (ADCs), noting the higher drug loading, better payload stability, better tissue penetrance, and thinks that will continue.

Protein 52

Protein DNA RNA Research 52

Drug Discovery World

OCTOBER 17, 2023

Today, spatial omics technologies enable imaging-based identification of cells in their native tissue context while simultaneously detecting hundreds of RNAs or tens of protein markers in the same cells. RA: Can spatial biology studies help drive advances in precision medicine? Let’s take CAR T cells as an example.

Gene Expression 52

Gene Expression Drugs Protein Gene 52

Drug Discovery World

MAY 30, 2023

From antibody-drug conjugates and RNA, to CRISPR and CAR-T therapy, DDW asked the drug discovery industry what the most important development in oncology over the last five years has been. At PhoreMost, we have been particularly excited about the emergence of targeted protein degradation (TPD) as a new therapeutic modality.

Research 52

Research Drugs Protein RNA 52

Delveinsight

JULY 29, 2021

billion in biobucks on the table to buy Teneobio and its suite of bispecific and multispecific antibody technologies focused on cancer and other disease targets. An antisense treatment, BIIB080 potentially aims at microtubule-linked protein tau (MAPT) messenger RNA (mRNA) and impedes tau protein production.

Drugs 98

Drugs Protein Life Science Trials 98

Drug Discovery World

FEBRUARY 6, 2023

This approach has led to the development of two software packages for RNA sequencing analysis and reproducible ribosomal profiling 1,2. For example, we recently collaborated with two sequencing laboratories to determine optimal parameters for RNA-Sequencing (RNA-Seq) in the context of a vaccine clinical trial.

Big Data 52

Big Data RNA Bioinformatics Vaccination 52

The Pharma Data

MARCH 11, 2021

Clinical trial to assess safety, immune response and reactogenicity, after preclinical data showed high neutralizing antibody levels. Preclinical data showed that two immunizations of the mRNA vaccine induced high neutralizing antibody levels that are comparable to the upper range of those observed in infected humans.

Clinical Trials 52

Clinical Trials Clinical Trials Vaccination Vaccine 52

The Pharma Data

JUNE 25, 2021

Available data were communicated with the European Medicines Agency (EMA). The vaccine candidate chosen for first clinical development, CVnCoV, is an optimized, non-chemically modified mRNA, encoding the prefusion stabilized full-length spike protein of the SARS-CoV-2 virus, and formulated within Lipid Nanoparticles (LNPs).

Vaccination 52

Vaccination Vaccine Trials Immune Response 52

pharmaphorum

DECEMBER 21, 2020

Compared with many of the established names in pharma these companies are young upstarts but they have managed to achieve what other big names in the industry have failed to do and harness the power of mRNA to make medicine. In this case that is the “spike” protein seen on the surface of the coronavirus that it uses to invade host cells.

Vaccination 85

Vaccination Vaccine Doctors Doctor 85

pharmaphorum

NOVEMBER 9, 2020

Results will be discussed with regulators worldwide and the European Medicines Agency has already begun its rolling review of data to hasten a decision on the clinical trial dossier. These cause the body to produce antibodies that neutralise the SARS-CoV-2 virus in the event of an infection.

Vaccination 91

Vaccination Vaccine Clinical Trials Clinical Trials 91

The Pharma Data

AUGUST 3, 2021

As part of Sanofi’s endeavor to accelerate the application of messenger RNA (mRNA) to develop therapeutics and vaccines, the company has entered into a definitive agreement with Translate Bio (NASDAQ: TBIO), a clinical-stage mRNA therapeutics company, under which Sanofi will acquire all outstanding shares of Translate Bio for $38.00

Vaccination 52

Vaccination Vaccine Development Clinical Trials 52

XTalks

DECEMBER 24, 2020

In addition to pharma and biotech companies who zealously began working to develop COVID-19 drugs and vaccines, companies from areas outside of science and medicine also stepped up to help during the pandemic. Most antibody drugs and vaccines have been developed to target parts of the spike protein. Drug Approvals.

Life Science 111

Life Science Vaccination Vaccine Gene 111

The Pharma Data

JANUARY 6, 2021

Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that the European Commission has granted a conditional marketing authorization (CMA) for COVID-19 Vaccine Moderna, allowing vaccination programs using the Moderna vaccine to be rolled out across the European Union.

Vaccination 52

Vaccination Vaccine Medicine Containment 52

pharmaphorum

JANUARY 17, 2023

As it stands, mRNA vaccines and therapeutics can only provide benefits if they can reach the living cells and be processed into protein. The intracellular barriers include endosomal escape, RNA sensors, and endonucleases. Those COVID vaccines that have experienced success are based around lipid nanoparticle delivery.

Vaccination 82

Vaccination Vaccine In-Vivo In-Vitro 82

The Pharma Data

JUNE 26, 2021

Sanofi Pasteur, the vaccines global business unit of Sanofi and Translate Bio (NASDAQ: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company, have initiated a Phase 1 clinical trial evaluating an mRNA-based investigational vaccine against seasonal influenza. Source link: [link].

Clinical Trials 52

Clinical Trials Clinical Trials Vaccination Vaccine 52

Drug Discovery World

AUGUST 10, 2022

Next, the advent of antibody treatments in 1997 created the first targeted cancer therapy 2. Later, scientists took advantage of antibodies’ natural tendency to seek out specific antigens and created antibody therapies that guide T cells towards the cells they are supposed to destroy. Identifying the right CAR T cell target.

Manufacturing 98

Manufacturing Gene Genome Genomics 98